You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

11 Results
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    exemestane
Nov 2020
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    letrozole
Nov 2020
Regimen
Intent: Neoadjuvant, Adjuvant
Jun 2020
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Aug 2020
Regimen
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Adjuvant
May 2020
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant, Curative, Palliative
Mar 2020
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue
Intent: Adjuvant, Curative, Palliative
Aug 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
    dexamethasone
Dec 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative, Curative, Adjuvant
Dec 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Dec 2020